{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:05:31Z","timestamp":1790269531853,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1053\/j.ajkd.2018.07.022","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T03:11:16Z","timestamp":1542683476000},"page":"776-778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?"],"prefix":"10.1053","volume":"72","author":[{"given":"Anushree","family":"Tiku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil V.","family":"Badve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.ajkd.2018.07.022_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrneph.2010.186","article-title":"Challenges of conducting\u00a0a trial of uric-acid-lowering therapy in CKD","volume":"7","author":"Badve","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2018.07.022_bib2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ndt\/gfu352","article-title":"Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study","volume":"30","author":"Jing","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1053\/j.ajkd.2018.07.022_bib3","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A\u00a0role for uric acid in the progression of renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2018.07.022_bib4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/ndt\/gft378","article-title":"Effects of uric acid-lowering therapy on renal outcomes: a systematic review and\u00a0meta-analysis","volume":"29","author":"Bose","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2018.07.022_bib5","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for\u00a0patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2018.07.022_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1053\/j.ajkd.2008.06.023","article-title":"Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort","volume":"52","author":"Levin","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2018.07.022_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ki.2013.47","article-title":"The GFR and GFR decline cannot be accurately estimated in type 2 diabetics","volume":"84","author":"Gaspari","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2018.07.022_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2010.531","article-title":"Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts","volume":"80","author":"Gansevoort","year":"2011","journal-title":"Kidney Int"},{"issue":"15","key":"10.1053\/j.ajkd.2018.07.022_bib9","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A\u00a0predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.ajkd.2018.07.022_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2018.07.022_bib11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.ajkd.2017.01.050","article-title":"Risks of adverse events in advanced CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"70","author":"Grams","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2018.07.022_bib12","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1681\/ASN.2015060687","article-title":"Past decline versus current eGFR and subsequent ESRD risk","volume":"27","author":"Kovesdy","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2018.07.022_bib13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/ndt\/gfv269","article-title":"Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials","volume":"31","author":"Badve","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2018.07.022_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1745-6215-15-26","article-title":"The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study","volume":"15","author":"Hosoya","year":"2014","journal-title":"Trials"},{"issue":"13","key":"10.1053\/j.ajkd.2018.07.022_bib15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2018.07.022_bib16","unstructured":"FDA. Drug Safety Communication: FDA to evaluate increased risk of heart-related death and 19 death from all causes with the gout medicine febuxostat (Uloric). https:\/\/www.fda.gov\/downloads\/drugs\/drugsafety\/ucm584803.pdf, Accessed July 11,\u00a02018."},{"issue":"4","key":"10.1053\/j.ajkd.2018.07.022_bib17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2215\/CJN.06790616","article-title":"The 3-year incidence of gout in elderly patients with CKD","volume":"12","author":"Tan","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2018.07.022_bib18","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1053\/j.ajkd.2018.07.022_bib19","first-page":"73","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Chapter 3: management of progression and complications of CKD","volume":"1","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"10.1053\/j.ajkd.2018.07.022_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11892-013-0381-0","article-title":"Uric acid lowering to prevent kidney function loss in diabetes: the Preventing Early Renal Function Loss (PERL) allopurinol study","volume":"13","author":"Maahs","year":"2013","journal-title":"Curr Diabetes Rep"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618309521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618309521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:14:20Z","timestamp":1759461260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638618309521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0272638618309521"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.07.022","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.06.028","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}